Price Chart

Profile

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
URL https://www.alimerasciences.com
Investor Relations URL http://investor.alimerasciences.com/index.cfm
HQ State/Province Georgia
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Value
Next Earnings Release May. 15, 2024 (est.)
Last Earnings Release Oct. 26, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
URL https://www.alimerasciences.com
Investor Relations URL http://investor.alimerasciences.com/index.cfm
HQ State/Province Georgia
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Value
Next Earnings Release May. 15, 2024 (est.)
Last Earnings Release Oct. 26, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A